Results for tag: "Meibomian Gland Dysfunction Drug"

The Meibomian Gland Dysfunction Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat Meibomian Gland Dysfunction (MGD), a condition that affects the eyelids and can lead to dry eye. Common treatments for MGD include antibiotics, anti-inflammatory drugs, and topical steroids. These drugs are used to reduce inflammation, reduce the production of meibomian gland secretions, and improve the quality of the tear film. The Meibomian Gland Dysfunction Drug market is highly competitive, with many companies offering products to treat MGD. Some of the major players in the market include Allergan, Bausch + Lomb, Santen Pharmaceuticals, and Shire. Other companies in the market include Akorn, Merck, and Sun Pharmaceuticals. Show Less Read more